Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2198 | 4878 | 40.8 | 70% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
14 | 4 | ORTHOPEDICS//DENTISTRY, ORAL SURGERY & MEDICINE//SPORT SCIENCES | 808941 |
444 | 3 | CARPAL TUNNEL SYNDROME//MEDIAN NERVE//ALDOSE REDUCTASE | 26401 |
2198 | 2 | ALDOSE REDUCTASE//ALDOSE REDUCTASE INHIBITOR//DIABETIC NEUROPATHY | 4878 |
2099 | 1 | DIABETIC NEUROPATHY//NERVE BLOOD FLOW//VASA NERVORUM | 2357 |
2952 | 1 | ALDOSE REDUCTASE//ALDOSE REDUCTASE INHIBITOR//AKR1B10 | 2104 |
24507 | 1 | C PEPTIDE//PROINSULIN C PEPTIDE//SECT CLIN PHYSIOL | 309 |
34694 | 1 | TRANSFUSION GELATIN//BALLISTOCONIDIA//CELL IRON DISTRIBUTION | 108 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ALDOSE REDUCTASE | authKW | 1862304 | 10% | 63% | 469 |
2 | ALDOSE REDUCTASE INHIBITOR | authKW | 912128 | 4% | 67% | 218 |
3 | DIABETIC NEUROPATHY | authKW | 669915 | 8% | 26% | 407 |
4 | POLYOL PATHWAY | authKW | 564524 | 3% | 66% | 136 |
5 | NERVE BLOOD FLOW | authKW | 289793 | 1% | 75% | 62 |
6 | AKR1B10 | authKW | 285547 | 1% | 89% | 51 |
7 | ALDO KETO REDUCTASE | authKW | 213335 | 2% | 33% | 103 |
8 | OCULAR THER EUT | address | 130331 | 1% | 77% | 27 |
9 | C PEPTIDE | authKW | 121263 | 3% | 15% | 128 |
10 | VASA NERVORUM | authKW | 111250 | 1% | 66% | 27 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 18095 | 24% | 0% | 1175 |
2 | Neurosciences | 4103 | 19% | 0% | 918 |
3 | Chemistry, Medicinal | 2145 | 7% | 0% | 337 |
4 | Clinical Neurology | 1956 | 10% | 0% | 494 |
5 | Pharmacology & Pharmacy | 1856 | 14% | 0% | 668 |
6 | Biochemistry & Molecular Biology | 1552 | 19% | 0% | 915 |
7 | Ophthalmology | 1305 | 5% | 0% | 245 |
8 | Pathology | 495 | 4% | 0% | 173 |
9 | Biophysics | 438 | 5% | 0% | 222 |
10 | Medicine, Research & Experimental | 384 | 5% | 0% | 220 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | OCULAR THER EUT | 130331 | 1% | 77% | 27 |
2 | MORRIS HOOD JR COMPREHENS DIABET | 101374 | 0% | 90% | 18 |
3 | SECT CLIN PHYSIOL | 35351 | 0% | 27% | 21 |
4 | IGBMCUPR BIOL STRUCT | 31290 | 0% | 100% | 5 |
5 | PATHOL 0612 | 26669 | 0% | 47% | 9 |
6 | MORRIS HOOD COMPREHENS DIABET | 25032 | 0% | 100% | 4 |
7 | SIMMONSCOOPER CANC | 18195 | 0% | 36% | 8 |
8 | JEWISH CARDIOVASC | 15640 | 0% | 50% | 5 |
9 | HARRY B AILEEN GORDON DIABET | 14300 | 0% | 57% | 4 |
10 | AATBSRB | 12516 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DIABETES | 36376 | 5% | 2% | 265 |
2 | DIABETOLOGIA | 28762 | 4% | 2% | 196 |
3 | EXPERIMENTAL DIABESITY RESEARCH | 18762 | 0% | 33% | 9 |
4 | JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 11091 | 1% | 5% | 33 |
5 | JOURNAL OF DIABETES AND ITS COMPLICATIONS | 8949 | 1% | 3% | 51 |
6 | EXPERIMENTAL DIABETES RESEARCH | 6382 | 0% | 6% | 18 |
7 | METABOLISM-CLINICAL AND EXPERIMENTAL | 5092 | 2% | 1% | 86 |
8 | JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY | 4897 | 1% | 2% | 50 |
9 | DIABETES RESEARCH AND CLINICAL PRACTICE | 4887 | 1% | 1% | 65 |
10 | DIABETES-METABOLISM RESEARCH AND REVIEWS | 4409 | 1% | 2% | 32 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ALDOSE REDUCTASE | 1862304 | 10% | 63% | 469 | Search ALDOSE+REDUCTASE | Search ALDOSE+REDUCTASE |
2 | ALDOSE REDUCTASE INHIBITOR | 912128 | 4% | 67% | 218 | Search ALDOSE+REDUCTASE+INHIBITOR | Search ALDOSE+REDUCTASE+INHIBITOR |
3 | DIABETIC NEUROPATHY | 669915 | 8% | 26% | 407 | Search DIABETIC+NEUROPATHY | Search DIABETIC+NEUROPATHY |
4 | POLYOL PATHWAY | 564524 | 3% | 66% | 136 | Search POLYOL+PATHWAY | Search POLYOL+PATHWAY |
5 | NERVE BLOOD FLOW | 289793 | 1% | 75% | 62 | Search NERVE+BLOOD+FLOW | Search NERVE+BLOOD+FLOW |
6 | AKR1B10 | 285547 | 1% | 89% | 51 | Search AKR1B10 | Search AKR1B10 |
7 | ALDO KETO REDUCTASE | 213335 | 2% | 33% | 103 | Search ALDO+KETO+REDUCTASE | Search ALDO+KETO+REDUCTASE |
8 | C PEPTIDE | 121263 | 3% | 15% | 128 | Search C+PEPTIDE | Search C+PEPTIDE |
9 | VASA NERVORUM | 111250 | 1% | 66% | 27 | Search VASA+NERVORUM | Search VASA+NERVORUM |
10 | NERVE CONDUCTION | 97304 | 2% | 18% | 85 | Search NERVE+CONDUCTION | Search NERVE+CONDUCTION |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GREWAL, AS , BHARDWAJ, S , PANDITA, D , LATHER, V , SEKHON, BS , (2016) UPDATES ON ALDOSE REDUCTASE INHIBITORS FOR MANAGEMENT OF DIABETIC COMPLICATIONS AND NON-DIABETIC DISEASES.MINI-REVIEWS IN MEDICINAL CHEMISTRY. VOL. 16. ISSUE 2. P. 120 -162 | 221 | 74% | 2 |
2 | MACCARI, R , OTTANA, R , (2015) TARGETING ALDOSE REDUCTASE FOR THE TREATMENT OF DIABETES COMPLICATIONS AND INFLAMMATORY DISEASES: NEW INSIGHTS AND FUTURE DIRECTIONS.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 58. ISSUE 5. P. 2047 -2067 | 132 | 86% | 13 |
3 | OATES, PJ , (2008) ALDOSE REDUCTASE, STILL A COMPELLING TARGET FOR DIABETIC NEUROPATHY.CURRENT DRUG TARGETS. VOL. 9. ISSUE 1. P. 14-36 | 143 | 76% | 94 |
4 | DEL CORSO, A , CAPPIELLO, M , MURA, U , (2008) FROM A DULL ENZYME TO SOMETHING ELSE: FACTS AND PERSPECTIVES REGARDING ALDOSE REDUCTASE.CURRENT MEDICINAL CHEMISTRY. VOL. 15. ISSUE 15. P. 1452-1461 | 146 | 80% | 28 |
5 | ZOCHODNE, DW , (2002) NERVE AND GANGLION BLOOD FLOW IN DIABETES: AN APPRAISAL.NEUROBIOLOGY OF DIABETIC NEUROPATHY. VOL. 50. ISSUE . P. 161 -202 | 140 | 82% | 18 |
6 | SUGIMOTO, K , MURAKAWA, Y , SIMA, AAF , (2000) DIABETIC NEUROPATHY - A CONTINUING ENIGMA.DIABETES-METABOLISM RESEARCH AND REVIEWS. VOL. 16. ISSUE 6. P. 408 -433 | 187 | 59% | 87 |
7 | OATES, PJ , (2002) POLYOL PATHWAY AND DIABETIC PERIPHERAL NEUROPATHY.NEUROBIOLOGY OF DIABETIC NEUROPATHY. VOL. 50. ISSUE . P. 325 -392 | 141 | 67% | 126 |
8 | CRABBE, MJC , GOODE, D , (1998) ALDOSE REDUCTASE: A WINDOW TO THE TREATMENT OF DIABETIC COMPLICATIONS?.PROGRESS IN RETINAL AND EYE RESEARCH. VOL. 17. ISSUE 3. P. 313 -383 | 158 | 69% | 56 |
9 | HUANG, L , HE, RZ , LUO, WH , ZHU, YS , LI, J , TAN, T , ZHANG, X , HU, Z , LUO, DX , (2016) ALDO-KETO REDUCTASE FAMILY 1 MEMBER B10 INHIBITORS: POTENTIAL DRUGS FOR CANCER TREATMENT.RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY. VOL. 11. ISSUE 2. P. 184 -196 | 80 | 76% | 2 |
10 | YAGIHASHI, S , MIZUKAMI, H , SUGIMOTO, K , (2011) MECHANISM OF DIABETIC NEUROPATHY: WHERE ARE WE NOW AND WHERE TO GO?.JOURNAL OF DIABETES INVESTIGATION. VOL. 2. ISSUE 1. P. 18-32 | 100 | 68% | 38 |
Classes with closest relation at Level 2 |